Participants with Pulmonary Arterial Hypertension MedDRA version: 21.1 Level: PT Classification code 10064911 Term: Pulmonary arterial hypertension System Organ Class: 10038738 - Respiratory, thoracic and mediastinal disorders
Conditions
Sponsors
Insmed Incorporated
Eligibility
Sex/Gender
All
Inclusion criteria
Inclusion criteria: 1. Participants must be = 18 to = 75 years at the time of signing the ICF. 2. Participants must have a diagnosis of WHO Group 1 PH (PAH) in any of the following subtypes: • idiopathic; • heritable or • drug/toxin-induced or CTD-associated PAH• Congenital heart disease-related with simple systemic-to-pulmonary shunt at least 1 year following repair 3. PAH diagnosis for at least 3 months. 4. New York Heart Association (NYHA)/WHO functional class II or III. 5. Medical history, physical examination, vital signs, ECG, and clinical laboratory results consistent with their degree of PAH and treatment. 6. Participants must be on stable PH therapy consisting of up to 2 medications from the following classes: • Endothelin receptor antagonists (eg, ambrisentan, bosentan, macitentan) • Phosphodiesterase type 5 inhibitors (eg, sildenafil, tadalafil) • Guanylate cyclase stimulator (eg, riociguat) 7. No change in PH medications (eg, ambrisentan, bosentan, macitentan, sildenafil, tadalafil, riociguat) or dosage for at least 30 days prior to Screening. 8. No change in long-term diuretic use dosage for at least 30 days prior to Screening (single or rescue doses allowed, per the Investigator). 9. Documented pre-bronchodilator predicted FEV1 =70% and FEV1/FVC ratio = 70% within 1 year of Screening. If documented spirometry is not available, pulmonary function testing will be performed during Screening. 10. At least two 6MWTs during Screening with a 6MWT distance between 150 and 450 meters in length where both values are within 15% of each other. 11. Right heart catheterization at Screening (or within 30 days prior to Screening, if available) with all the following hemodynamic findings: • Mean PAP = 25 mmHg at rest • PCWP = 15 mmHg • PVR of = 5 WU 12. BMI within the range 18.0-37.0 kg/m2 (inclusive). 13. Male and female participants must use contraceptives that are consistent with local regulations regarding the methods of contraception for those participating in clinical studies. • Male participants: Male participants who are not sterile and have female partners of childbearing potential, must be using effective contraception from Day 1 to at least 90 days after the last dose of study drug. Such methods include true abstinence (refraining from heterosexual intercourse during the study), combined (estrogen and progestogen containing) or progestogen-only hormonal contraception associated with inhibition of ovulation, intrauterine devices, intrauterine hormone-releasing systems. • Female participants: Women must be postmenopausal (defined as no menses for 12 months without an alternative medical cause), surgically sterile, (ie, hysterectomy and/or bilateral salpingo-oopherectomy), or using highly effective contraception methods (ie, methods that alone or in combination achieve 40 mIU/mL should be performed to be considered infertile. All WOCBP must hav
Exclusion criteria
Exclusion criteria: 1. History of PH other than idiopathic, hereditary, drug/toxin-induced, repaired simple congenital heart disease, or CTD-associated PAH (eg, complex congenital heart disease-associated PAH, portal hypertension-associated PAH, PH belonging to Groups 2 through 5). 2. Allergy, or documented hypersensitivity or contraindication, to TPIP or TRE or mannitol (an excipient of the TPIP formulation). 3. Per the Investigator’s discretion, previous intolerance to prostacyclin analogues or receptor agonists or previous chronic use (>30 days) of a prostacyclin analogue or receptor agonist within 30 days of the Screening Visit. 4. QTcF interval > 480 ms on resting ECG at Screening, not including participants with right bundle branch block (RBBB) leading to a prolongation of the QRS. 5. Any known ventricular or supraventricular tachyarrhythmia except for paroxysmal atrial fibrillation and any symptomatic bradycardia. 6. History of heart disease including left ventricular ejection fraction (LVEF) = 40% or clinically significant valvular, constrictive, or symptomatic atherosclerotic heart disease. 7. Systolic BP 2 × ULN) • Bilirubin > 1.5 × ULN (isolated bilirubin > 1.5 × ULN; ULN is acceptable if bilirubin is fractionated and direct bilirubin < 35%) • Known hepatic or biliary abnormalities, not including Gilbert's syndrome or asymptomatic gallstones 13. History of HIV infection 14. Established diagnosis of hepatitis B viral infection, or positive for HBsAg at the time of Screening. • Participants who have gained immunity for hepatitis B virus infection after vaccination are eligible for the study. • Participants with positive HBcAbs are eligible for the study only if the hepatitis B virus DNA level is undetectable. 15. Established diagnosis of hepatitis C viral infection at the time of screening. Participants positive for hepatitis C antibody are eligible for the study only if hepatitis C virus RNA is negative. 16. Active and current symptomatic COVID-19 or previous severe disease and/or hospitalization due to COVID-19 17. Use of live attenuated vaccines within 30 Days of the Screening Visit. 18. Participants with Down’s Syndrome. 19. History of abnormal bleeding or bruising with a platelet count of <100,000/µL at Screening. 20. History of organ transplantation. 21. Known or suspected immunodeficiency disorder 22. Severe concomitant illness(es) that, in the Investigator's judgment, would adversely affect the participant’s participation in the study. 23. Any clinically significant abnormal laboratory values at Screening or diseases or disorders (eg, cardiovascular, pulmonary, gastrointestinal, liver, kidney, neurological, musculoskeletal, endocrine, metabolic, psychiatric, physical impairment) that, in the opinion of the Investigator, may put the participant at risk by participating in the study, or interfere with the participant’s treatment, assessment, or influence the results of the study, or have compliance issues with the study or have
Design outcomes
Primary
| Measure | Time frame |
|---|---|
| Main Objective: To assess the effect of Treprostinil Palmitil Inhalation Powder (TPIP) compared with placebo on Pulmonary Vascular Resistance (PVR);Secondary Objective: -To assess the effect of TPIP compared with placebo on exercise capacity -To assess the safety and tolerability of TPIP compared with placebo -To evaluate the PK of TP and TRE in plasma -To evaluate the effect of TPIP compared with placebo on the concentration of NT-proBNP in blood;Primary end point(s): Change from Baseline in PVR;Timepoint(s) of evaluation of this end point: at Week 16 | — |
Secondary
| Measure | Time frame |
|---|---|
| Secondary end point(s): -Change from Baseline in 6MWT distance -Percent change from Baseline in 6MWT distance - Frequency of AEs and changes from Baseline in clinical laboratory evaluations, vital signs, ECG, and physical examination - Plasma PK parameters of TP and TRE, including Cmax, tmax, AUC24, AUC8, AUClast, CL/F, Vd/F, and t½. - Change from Baseline in the concentration of NT-proBNP;Timepoint(s) of evaluation of this end point: - at Week 5, Week 10, and Week 16 - at Week 5, Week 10, and Week 16 - over the 16-week treatment period - on Day 1 and at Week 10 - at Week 5, Week 10 and Week 16 | — |
Countries
Argentina, Australia, Austria, Belgium, Brazil, Denmark, Germany, Italy, Japan, Malaysia, Mexico, Philippines, Serbia, Spain, Switzerland, United Kingdom, United States
Contacts
Public ContactRegulatory Affairs Manager EU
Insmed Switzerland GmbH
Outcome results
None listed